Medtronic Net Long-Term Debt 2010-2025 | MDT
Medtronic annual/quarterly net long-term debt history and growth rate from 2010 to 2025. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
- Medtronic net long-term debt for the quarter ending April 30, 2025 was $3.209B, a 0% increase year-over-year.
- Medtronic net long-term debt for the twelve months ending April 30, 2025 was $12.836B, a 0% increase year-over-year.
- Medtronic annual net long-term debt for 2025 was $3.209B, a 0% decline from 2024.
- Medtronic annual net long-term debt for 2024 was $0B, a 100% decline from 2023.
- Medtronic annual net long-term debt for 2023 was $-0.603B, a 60200% increase from 2022.
| Medtronic Annual Net Long-Term Debt (Millions of US $) |
|
|---|---|
| 2025 | $3,209 |
| 2024 | $N/A |
| 2023 | $-603 |
| 2022 | $-1 |
| 2021 | $-195 |
| 2020 | $-542 |
| 2019 | $-154 |
| 2018 | $-7,349 |
| 2017 | $1,277 |
| 2016 | $-5,132 |
| 2015 | $18,674 |
| 2014 | $1,429 |
| 2013 | $766 |
| 2012 | $1,186 |
| 2011 | $-1,603 |
| 2010 | $2,980 |
| 2009 | $950 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $114.929B | $33.537B |
| Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $215.166B | 25.24 |
| Boston Scientific (BSX) | United States | $153.330B | 38.38 |
| Stryker (SYK) | United States | $148.630B | 31.08 |
| EssilorLuxottica (ESLOY) | France | $131.070B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.764B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.126B | 24.61 |
| ResMed (RMD) | United States | $37.818B | 28.41 |
| GE HealthCare Technologies (GEHC) | United States | $34.781B | 16.51 |
| Agilent Technologies (A) | United States | $32.381B | 21.11 |
| Terumo (TRUMY) | Japan | $23.911B | 31.06 |
| Koninklijke Philips (PHG) | Netherlands | $23.688B | 16.62 |
| Insulet (PODD) | United States | $20.003B | 78.52 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.437B | 11.84 |
| Baxter (BAX) | United States | $14.251B | 10.64 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.214B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $10.417B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.705B | 23.33 |
| Lantheus Holdings (LNTH) | United States | $4.855B | 12.25 |
| Prestige Consumer Healthcare (PBH) | United States | $3.744B | 16.73 |
| Perrigo (PRGO) | Ireland | $3.706B | 9.39 |
| Haemonetics (HAE) | United States | $3.485B | 15.88 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.307B | 27.48 |
| ICU Medical (ICUI) | United States | $3.014B | 22.23 |
| LeMaitre Vascular (LMAT) | United States | $1.802B | 40.29 |
| QuidelOrtho (QDEL) | United States | $1.721B | 11.84 |
| AtriCure (ATRC) | United States | $1.449B | 0.00 |
| Acuren (TIC) | United States | $1.408B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.244B | 12.63 |
| Phibro Animal Health (PAHC) | United States | $1.192B | 15.24 |
| Green Thumb Industries (GTBIF) | United States | $1.190B | 26.76 |
| Neogen (NEOG) | United States | $1.029B | 13.17 |
| BioLife Solutions (BLFS) | United States | $0.996B | 0.00 |
| InMode (INMD) | Israel | $0.878B | 8.85 |
| Kestra Medical Technologies (KMTS) | United States | $0.816B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.670B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.625B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.619B | 0.00 |
| Owens & Minor (OMI) | United States | $0.599B | 4.97 |
| Evolus (EOLS) | United States | $0.593B | 0.00 |
| CeriBell (CBLL) | United States | $0.563B | 0.00 |
| Valneva SE (VALN) | France | $0.557B | 0.00 |
| Surmodics (SRDX) | United States | $0.432B | 0.00 |
| SNDL (SNDL) | Canada | $0.405B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.336B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.315B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.314B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.298B | 10.97 |
| Quanterix (QTRX) | United States | $0.268B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.267B | 0.00 |
| Cerus (CERS) | United States | $0.260B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.257B | 21.63 |
| Aurora Cannabis (ACB) | Canada | $0.255B | 75.50 |
| OraSure Technologies (OSUR) | United States | $0.239B | 0.00 |
| ZimVie (ZIMV) | United States | $0.235B | 10.68 |
| Sanara MedTech (SMTI) | United States | $0.234B | 0.00 |
| Brainsway (BWAY) | Israel | $0.228B | 60.45 |
| Biote (BTMD) | United States | $0.220B | 6.18 |
| Canopy Growth (CGC) | Canada | $0.200B | 0.00 |
| High Tide (HITI) | Canada | $0.199B | 0.00 |
| Omeros (OMER) | United States | $0.197B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.195B | 0.00 |
| Organigram Global (OGI) | Canada | $0.194B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.180B | 14.69 |
| TriSalus Life Sciences (TLSI) | United States | $0.174B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.149B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.120B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.110B | 0.00 |
| Jin Medical (ZJYL) | China | $0.103B | 0.00 |
| Fonar (FONR) | United States | $0.099B | 12.80 |
| MacroGenics (MGNX) | United States | $0.093B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.091B | 0.00 |
| Veru (VERU) | United States | $0.087B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Apyx Medical (APYX) | United States | $0.085B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.076B | 0.00 |
| Zynex (ZYXI) | United States | $0.070B | 0.00 |
| InterCure (INCR) | Israel | $0.069B | 0.00 |
| Agape ATP (ATPC) | $0.065B | 0.00 | |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| ImmuCell (ICCC) | United States | $0.060B | 0.00 |
| Safety Shot (SHOT) | United States | $0.055B | 0.00 |
| United-Guardian (UG) | United States | $0.042B | 14.52 |
| Nephros (NEPH) | United States | $0.039B | 52.07 |
| Rockwell Medical (RMTI) | United States | $0.038B | 0.00 |
| Modular Medical (MODD) | United States | $0.037B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |